USPSTF recommends pharmacotherapy for tobacco interventions in nonpregnant adults

Last week, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation statement in JAMA updating its 2015 recommendation on tobacco smoking treatment. The recommendation statement concludes with high certainty that the net benefit of behavioral interventions and U.S. Food and Drug Administration (FDA)–approved pharmacotherapy for tobacco smoking cessation, alone or combined, in nonpregnant adults who smoke is substantial. The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco and provide behavioral interventions and FDA‐approved pharmacotherapy for cessation to nonpregnant adults who use tobacco, and that clinicians ask all pregnant persons about tobacco use, advise them to stop using tobacco and provide behavioral interventions for cessation to pregnant persons who use tobacco. However, the USPSTF found that the balance of benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant persons is insufficient.